No. The company made no mention of it "meeting all endpoints." There was in fact no mention of plasma concentrations or tumor response. They did see signs of p53 activity, which is encouraging. In this aspect, the trial was a success. Hopefully it was the limited dosing regimen that obviated efficacy outcomes. It was the reason the company discontinued the trial. (Yeah yeah we know, the results were so darn good that we decided not to spend any more money on it. That's some folks idea of dealing with reality.)
News 
Market Data 
Discover 
AI
